BridgeMD
Tests treatment safety and results for RCC, Renal Cell Cancer
Official title Prospective Study on the Safety and Efficacy of Robot-Assisted Laparoscopic Partial Nephrectomy With Renal Artery Off-Clamp in the Treatment of cT1 Renal Tumors
ClinicalTrials.gov ID: NCT06908902
What this study is testing
- What it's testing
- Renal tumors are common urological cancers, with over 430,000 new cases and more than 170,000 deaths globally in 2020. In China, renal cancer ranks third among urological malignancies, with an increasing incidence.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 80
You may be able to join if
- Imaging examination confirms a T1 renal tumor (including T1a and T1b), and the investigator deems partial nephrectomy to be beneficial.
- Age ranges from 18 to 90 years.
- No history of severe kidney disease or autoimmune disorders.
- Cardiopulmonary function indicates the ability to tolerate major abdominal surgery.
- ECOG performance status score is 0 or 1.
You likely can't join if
- Imaging assessment shows a tumor stage of ≥T2.
- Imaging indicates that the tumor is located in the renal pelvis or is a Wilms' tumor, etc.
- The investigator considers the patient unsuitable for partial nephrectomy.
- Major surgery or significant trauma occurred within 28 days prior to enrollment.
- Live vaccine received within 28 days prior to enrollment.
- Severe chronic or active infections requiring systemic antibacterial, antifungal, or antiviral treatment occurred within 14 days prior to enrollment.
See the full eligibility criteria
- Imaging examination confirms a T1 renal tumor (including T1a and T1b), and the investigator deems partial nephrectomy to be beneficial.
- Age ranges from 18 to 90 years.
- No history of severe kidney disease or autoimmune disorders.
- Cardiopulmonary function indicates the ability to tolerate major abdominal surgery.
- ECOG performance status score is 0 or 1.
- Willingness to undergo zero-ischemia partial nephrectomy and able to provide written informed consent, understanding and agreeing to comply with the study requirements and evaluation schedule.
- Imaging assessment shows a tumor stage of ≥T2.
- Imaging indicates that the tumor is located in the renal pelvis or is a Wilms' tumor, etc.
- The investigator considers the patient unsuitable for partial nephrectomy.
- Major surgery or significant trauma occurred within 28 days prior to enrollment.
- Live vaccine received within 28 days prior to enrollment.
- Severe chronic or active infections requiring systemic antibacterial, antifungal, or antiviral treatment occurred within 14 days prior to enrollment.
- Any traditional Chinese medicine or herbal supplements for cancer treatment taken within 14 days prior to enrollment.
- Participation in any other clinical trials.
The study team makes the final eligibility decision.
Where it's taking place
- Nanjing, Jiangsu, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 80 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Nanjing, Jiangsu, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.